Objective: To investigate the selective mechanism of dehydroepiandrosterone (DHEA) for osteoblast via ERβ.
Methods: High expression of ERβ in hMG63-ERβ group (infected with pWPT-ERβ), gene silencing of ERβ in hMG63-shERβ group (infected with pLVTHM-GFP/ERβ-shRNA) and hMG63 group (control) were cultured and treated with 1×10(-7) mol/L DHEA, with or without U0126 and etoposide. The proliferation and apoptosis of hMG63 were evaluated by flow cytometry. The mRNA level of estrogen receptor subtype was detected by reverse transcription-PCR.
Results: The expression of ERβ in hMG63-ERβ group and hMG63-shERβ group were increased 7.39 times and decreased 17% compared with that in hMG63 group (control). DHEA could increase ERβ expression in hMG63 in each group, however, it did not influence the expression of ERα mRNA. When the level of ERβ was high, DHEA could accelerate the proliferation [proliferation index were (81.6 ± 7.6)% in hMG63-ERβ, (75.0 ± 5.3)% in hMG63, P < 0.05] and inhibit the apoptosis [apoptosis rate were (12.2 ± 1.6)% in hMG63-ERβ, (14.6 ± 1.5)% in hMG63, P < 0.01], which was blocked by U0126 [proliferation index were (33.2 ± 2.0)% in hMG63-ERβ, (41.2 ± 2.4)% in hMG63, apoptosis rate were (40.5 ± 4.3)% in hMG63-ERβ, (43.3 ± 4.1)% in hMG63, all P < 0.05]. When the expression of ERβ was silenced, DHEA could not inhibit the apoptosis of hMG63 anymore.
Conclusion: DHEA selectively act on osteoblasts via the dominant expression of ERβ.
Download full-text PDF |
Source |
---|
ACS Chem Neurosci
January 2025
Jiangxi Key Laboratory of Neurological Diseases, Department of Neurosurgery, the first Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwaizheng Street, Nanchang, Jiangxi 330006, China.
Patients with spinal cord injury (SCI) may develop depression, which can affect their rehabilitation. However, the underlying mechanism of depression in SCI patients remains unclear. Previous studies have revealed increased p38 MAPK phosphorylation in the rat hippocampus after SCI, accompanied by depression-like behaviors.
View Article and Find Full Text PDFDNA Cell Biol
January 2025
Department of Anesthesiology, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Lung cancer represents a significant global health burden, with non-small cell lung cancer (NSCLC) being the most common subtype. The current standard of care for NSCLC has limited efficacy, highlighting the necessity for innovative treatment options. Lidocaine, traditionally recognized as a local anesthetic, has emerged as a compound with potential antitumor and anti-inflammatory capabilities.
View Article and Find Full Text PDFFASEB J
January 2025
Department of Medicine, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Nuclear factor of activated T-cells 5 (NFAT5) is a transcription factor known for its role in osmotic stress adaptation in the renal inner medulla, due to the osmotic gradient that is generated between the renal cortex and renal inner medulla. However, its broader implications in kidney injury and chronic kidney disease (CKD) are less understood. Here we used two different Cre deleter mice (Ksp1.
View Article and Find Full Text PDFCancer Res Commun
January 2025
University of Minnesota, Minnesota, MN, United States.
Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Importance: Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants' decision-making is critical for enhancing trial recruitment.
Objective: To evaluate the attitudes of patients with cancer and their relatives toward clinical trial participation, identifying key barriers and motivators that affect their willingness to engage in such trials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!